http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2006527729-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-422 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 |
| filingDate | 2004-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2006-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2006527729-A |
| titleOfInvention | 1-Phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivatives and related compounds as factor XA inhibitors for the treatment of acute vascular disease |
| abstract | The present invention relates to a compound of formula (I): [Where: R 1 is: (Each ring may contain additional heteroatoms N; Z is an optional substituent halogen; alk is alkylene or alkenylene; T is S, O or NH) A group selected from: R 2 is —C 1-6 alkyl, —C 1-3 alkyl CN, —C 0-3 alkyl R c , —C 1-3 alkyl R f , —C 2-3 alkyl NR a R b , —C 2-3 alkyl OC 1-6 alkyl, —C 2-3 alkyl OC 1-3 alkyl CONR a R b , wherein R 2 is other than C 2-3 alkylmorpholino; R a and R b are independently hydrogen, —C 1-6 alkyl, or, together with the N atom to which they are attached, substituted by —C 1-4 alkyl. Forming a 5-, 6- or 7-membered non-aromatic heterocyclic ring, which may contain additional heteroatoms selected from O, N or S, wherein S heteroatoms are May be substituted by O, ie S (O) n ; R c is —C 3-6 cycloalkyl; R f is phenyl or at least one heteroatom selected from O, N or S, optionally substituted by 0 to 2 groups selected from —C 1-4 alkyl or —NH 2 A 5- or 6-membered aromatic heterocyclic ring containing, wherein the S or N heteroatom may be substituted by O, ie S (O) n or N-oxide Well; n is 0-2; X represents halogen, —C 1-4 alkyl, —C 2-4 alkenyl, —CN, —CF 3 , —NR a R b , —C 0-4 alkyl OR e , —C (O) R d, respectively. And 5 containing at least one heteroatom selected from phenyl, or O, N or S, optionally substituted by 0 to 2 groups selected from —C (O) NR a R b Or a 6-membered aromatic heterocyclic group; R e is hydrogen or —C 1-6 alkyl; Y is hydrogen, halogen, —C 1-4 alkyl, —C 2-4 alkenyl, —NR a R b , —NO 2 , —C (O) NR a R b , —N (C 1-4 alkyl) (CHO), —NHCOC 1-4 alkyl, —NHSO 2 R d , —C 0-4 alkyl OR e , —C (O) R d , —S (O) n R d or —S (O) 2 NR a substituent selected from a R b ; R d is —C 1-6 alkyl] And / or a pharmaceutically acceptable derivative thereof. Further, a method for producing a compound represented by the formula (I), a pharmaceutical composition containing the compound represented by the formula (I) and a pharmaceutical, particularly a formula (I used for improving clinical symptoms involving a factor Xa inhibitor ). |
| priorityDate | 2003-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 86.